Symbols / XFOR Stock $3.77 +3.57% X4 Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
XFOR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · United States
Market Cap 355.59M
Enterprise Value 199.12M
Income -99.72M
Sales 9.01M
FCF (ttm) -55.17M
Book/sh 1.79
Cash/sh 2.48
Employees 45
Insider 10d —
IPO Nov 16, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.19
PEG —
P/S 39.45
P/B 2.11
P/C —
EV/EBITDA -2.22
EV/Sales 22.09
Quick Ratio 9.88
Current Ratio 10.18
Debt/Eq 45.86
LT Debt/Eq —
EPS (ttm) -2.07
EPS next Y -0.90
EPS Growth —
Revenue Growth -90.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-06
ROA -28.33%
ROE -104.21%
ROIC —
Gross Margin 81.82%
Oper. Margin -7.48%
Profit Margin 0.00%
Shs Outstand 94.32M
Shs Float 57.41M
Insider Own 0.61%
Instit Own 99.59%
Short Float 3.31%
Short Ratio 7.90
Short Interest 3.12M
52W High 4.83
vs 52W High -21.95%
52W Low 1.35
vs 52W Low 179.26%
Beta 0.32
Impl. Vol. —
Rel Volume 0.60
Avg Volume 454.03K
Volume 271.45K
Target (mean) $11.67
Tgt Median $12.00
Tgt Low $10.00
Tgt High $13.00
# Analysts 3
Recom Strong_buy
Prev Close $3.64
Price $3.77
Change 3.57%
About

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.67
Mean price target
2. Current target
$3.77
Latest analyst target
3. DCF / Fair value
$-10.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.77
Low
$10.00
High
$13.00
Mean
$11.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-09 init Guggenheim — → Buy $12
2025-12-05 main Stifel Buy → Buy $10
2025-11-10 main HC Wainwright & Co. Buy → Buy $5
2025-08-29 main Stifel Buy → Buy $9
2025-08-13 main HC Wainwright & Co. Buy → Buy $4
2025-05-02 main HC Wainwright & Co. Buy → Buy $7
2025-03-27 reit HC Wainwright & Co. Buy → Buy $2
2025-03-26 reit Cantor Fitzgerald Overweight → Overweight $3
2025-02-07 reit HC Wainwright & Co. Buy → Buy $2
2025-01-14 reit HC Wainwright & Co. Buy → Buy $2
2024-11-14 main HC Wainwright & Co. Buy → Buy $2
2024-11-14 main Stifel Buy → Buy $4
2024-06-28 reit HC Wainwright & Co. Buy → Buy $5
2024-05-31 reit Cantor Fitzgerald Overweight → Overweight $5
2024-04-30 main HC Wainwright & Co. Buy → Buy $5
2024-03-22 reit HC Wainwright & Co. Buy → Buy $3
2023-12-12 down B. Riley Securities Buy → Neutral $1
2023-08-11 reit HC Wainwright & Co. Buy → Buy $3
2023-05-17 main Stifel Buy → Buy $5
2023-05-05 reit HC Wainwright & Co. — → Buy $3
News
RSS: Latest XFOR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-12 KIRSKE DAVID H. SR Chief Financial Officer — 16,961 $4.29 $72,820
2025-10-23 CRAIG ADAM R Officer and Director — 86,206 $2.90 $249,997
2025-08-14 KIRSKE DAVID H. SR Chief Financial Officer — 193,254 $0.00 $0
2025-08-14 VOLPONE JOHN President — 289,881 $0.00 $0
2025-08-14 CRAIG ADAM R Officer and Director — 289,881 $0.00 $0
2025-06-09 STEWART MURRAY Director — 1,500 $0.00 $0
2025-06-09 BRIDGER GARY J Director — 1,500 $0.00 $0
2025-06-09 DE CRAECKER FRANCOISE Director — 1,500 $0.00 $0
2025-06-09 WOODS KEITH Director — 1,500 $0.00 $0
2025-06-09 WYZGA MICHAEL S Director — 1,500 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
35.11
+1273.21%
2.56
0.00
0.00
Operating Revenue
35.11
+1273.21%
2.56
0.00
0.00
Cost Of Revenue
5.76
+622.33%
0.80
0.00
0.00
Reconciled Cost Of Revenue
5.76
+622.33%
0.80
0.00
0.00
Gross Profit
29.36
+1567.95%
1.76
0.00
0.00
Operating Expense
116.24
-18.81%
143.16
+33.15%
107.52
+22.08%
88.08
Research And Development
72.72
-10.93%
81.64
+13.37%
72.02
+17.95%
61.06
Selling General And Administration
43.52
-29.26%
61.52
+73.27%
35.51
+31.40%
27.02
General And Administrative Expense
—
—
—
—
Other Gand A
—
—
—
—
Total Expenses
122.00
-15.26%
143.96
+33.89%
107.52
+22.08%
88.08
Operating Income
-86.88
+38.56%
-141.40
-31.51%
-107.52
-22.08%
-88.08
Total Operating Income As Reported
-86.88
-138.68%
-36.40
+66.15%
-107.52
-22.79%
-87.57
EBITDA
-69.00
-150.24%
-27.58
+70.94%
-94.89
-6.22%
-89.33
Normalized EBITDA
-81.78
+39.20%
-134.50
-31.91%
-101.97
-11.39%
-91.54
Reconciled Depreciation
1.28
+60.43%
0.80
+89.98%
0.42
-18.32%
0.51
EBIT
-70.28
-147.72%
-28.37
+70.23%
-95.31
-6.08%
-89.85
Total Unusual Items
12.78
-88.05%
106.93
+1411.56%
7.07
+220.09%
2.21
Total Unusual Items Excluding Goodwill
12.78
-88.05%
106.93
+1411.56%
7.07
+220.09%
2.21
Special Income Charges
0.00
-100.00%
105.00
0.00
-100.00%
0.51
Impairment Of Capital Assets
—
—
0.00
0.00
Net Income
-79.20
-111.48%
-37.45
+62.98%
-101.17
-7.78%
-93.87
Pretax Income
-79.16
-113.13%
-37.14
+63.26%
-101.09
-7.73%
-93.84
Net Non Operating Interest Income Expense
-4.30
-43.38%
-3.00
-150.96%
-1.20
+68.34%
-3.77
Interest Expense Non Operating
8.88
+1.23%
8.77
+51.77%
5.78
+44.68%
3.99
Net Interest Income
-4.30
-43.38%
-3.00
-150.96%
-1.20
+68.34%
-3.77
Interest Expense
8.88
+1.23%
8.77
+51.77%
5.78
+44.68%
3.99
Interest Income Non Operating
4.58
-20.68%
5.77
+25.91%
4.58
+1992.24%
0.22
Interest Income
4.58
-20.68%
5.77
+25.91%
4.58
+1992.24%
0.22
Other Income Expense
12.03
-88.79%
107.26
+1306.14%
7.63
+483.90%
-1.99
Other Non Operating Income Expenses
-0.75
-326.81%
0.33
-40.07%
0.55
+113.20%
-4.20
Gain On Sale Of Security
12.78
+562.76%
1.93
-72.75%
7.07
+315.87%
1.70
Tax Provision
0.04
-86.77%
0.31
+297.44%
0.08
+178.57%
0.03
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
2.68
-88.05%
22.45
+1411.56%
1.49
+220.09%
0.46
Net Income Including Noncontrolling Interests
-79.20
-111.48%
-37.45
+62.98%
-101.17
-7.78%
-93.87
Net Income From Continuing Operation Net Minority Interest
-79.20
-111.48%
-37.45
+62.98%
-101.17
-7.78%
-93.87
Net Income From Continuing And Discontinued Operation
-79.20
-111.48%
-37.45
+62.98%
-101.17
-7.78%
-93.87
Net Income Continuous Operations
-79.20
-111.48%
-37.45
+62.98%
-101.17
-7.78%
-93.87
Normalized Income
-89.29
+26.76%
-121.92
-14.21%
-106.76
-11.65%
-95.61
Net Income Common Stockholders
-79.20
-111.48%
-37.45
+62.98%
-101.17
-4.93%
-96.41
Otherunder Preferred Stock Dividend
—
0.00
0.00
-100.00%
2.55
Diluted EPS
-1.87
+67.19%
-5.70
+66.61%
-17.07
+62.57%
-45.60
Basic EPS
-1.87
+67.19%
-5.70
+66.61%
-17.07
+62.57%
-45.60
Basic Average Shares
42.29
+531.04%
6.70
+13.08%
5.93
+179.91%
2.12
Diluted Average Shares
42.29
+531.04%
6.70
+13.08%
5.93
+179.91%
2.12
Diluted NI Availto Com Stockholders
-79.20
-111.48%
-37.45
+62.98%
-101.17
-4.93%
-96.41
Gain On Sale Of PPE
0.00
-100.00%
105.00
0.00
-100.00%
0.51
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
290.46
+98.34%
146.45
-0.55%
147.26
-5.35%
155.59
Current Assets
261.58
+133.19%
112.17
-8.11%
122.08
-5.13%
128.68
Cash Cash Equivalents And Short Term Investments
253.00
+147.89%
102.06
-10.64%
114.22
-6.16%
121.72
Cash And Cash Equivalents
217.05
+289.68%
55.70
-43.86%
99.22
-18.49%
121.72
Other Short Term Investments
35.95
-22.46%
46.36
+209.07%
15.00
0.00
Receivables
0.57
-66.49%
1.71
+204.27%
0.56
-51.22%
1.15
Accounts Receivable
0.57
-46.45%
1.07
0.00
—
Other Receivables
—
0.64
+13.88%
0.56
-51.22%
1.15
Inventory
4.48
+59.00%
2.82
0.00
—
Raw Materials
1.38
-9.61%
1.53
0.00
—
Work In Process
2.52
+314.14%
0.61
0.00
—
Finished Goods
0.58
-14.85%
0.68
0.00
—
Prepaid Assets
—
—
—
—
Other Current Assets
3.53
-36.88%
5.59
-23.43%
7.30
+25.68%
5.81
Total Non Current Assets
28.88
-15.72%
34.27
+36.10%
25.18
-6.42%
26.91
Net PPE
1.59
-67.13%
4.84
-24.30%
6.39
-23.26%
8.33
Gross PPE
2.82
-58.14%
6.74
-15.85%
8.01
-16.18%
9.56
Accumulated Depreciation
-1.23
+35.26%
-1.90
-17.54%
-1.62
-31.84%
-1.23
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.17
-34.40%
1.78
+20.00%
1.49
+1.37%
1.47
Other Properties
1.43
-69.88%
4.73
-24.87%
6.30
-19.92%
7.87
Leases
0.23
+0.00%
0.23
+0.00%
0.23
+0.00%
0.23
Goodwill And Other Intangible Assets
26.60
-2.74%
27.35
+57.63%
17.35
+0.00%
17.35
Goodwill
17.35
+0.00%
17.35
+0.00%
17.35
+0.00%
17.35
Other Intangible Assets
9.25
-7.50%
10.00
—
—
Other Non Current Assets
0.69
-66.73%
2.08
+44.85%
1.44
+17.22%
1.23
Total Liabilities Net Minority Interest
104.17
-16.19%
124.30
+29.26%
96.16
+17.94%
81.53
Current Liabilities
25.76
-21.66%
32.88
+43.81%
22.86
+2.41%
22.32
Payables And Accrued Expenses
20.00
+7.66%
18.57
+36.89%
13.57
+2.64%
13.22
Payables
5.70
-33.93%
8.62
-3.64%
8.95
+15.04%
7.78
Accounts Payable
5.70
-33.93%
8.62
-3.64%
8.95
+15.04%
7.78
Current Accrued Expenses
14.30
+43.69%
9.95
+115.36%
4.62
-15.09%
5.44
Pensionand Other Post Retirement Benefit Plans Current
4.30
-67.03%
13.05
+59.28%
8.20
+24.32%
6.59
Current Debt And Capital Lease Obligation
0.99
-20.54%
1.25
+13.83%
1.10
-56.27%
2.51
Current Debt
—
—
—
1.31
Other Current Borrowings
—
—
—
1.31
Current Capital Lease Obligation
0.99
-20.54%
1.25
+13.83%
1.10
-8.26%
1.20
Current Deferred Liabilities
0.46
0.00
—
—
Current Deferred Revenue
0.46
0.00
—
—
Total Non Current Liabilities Net Minority Interest
78.41
-14.23%
91.42
+24.73%
73.30
+23.79%
59.21
Long Term Debt And Capital Lease Obligation
76.29
-0.71%
76.83
+34.37%
57.18
+59.25%
35.91
Long Term Debt
76.29
+1.15%
75.42
+38.22%
54.57
+68.93%
32.30
Long Term Capital Lease Obligation
0.00
-100.00%
1.41
-46.02%
2.61
-27.50%
3.60
Non Current Deferred Liabilities
0.62
0.00
—
—
Non Current Deferred Revenue
0.62
0.00
—
—
Other Non Current Liabilities
0.53
-36.82%
0.83
+92.36%
0.43
+149.71%
0.17
Stockholders Equity
186.29
+741.08%
22.15
-56.65%
51.10
-30.99%
74.05
Common Stock Equity
186.29
+741.08%
22.15
-56.65%
51.10
-30.99%
74.05
Capital Stock
0.09
+1416.67%
0.01
-96.41%
0.17
+36.89%
0.12
Common Stock
0.09
+1416.67%
0.01
-96.41%
0.17
+36.89%
0.12
Preferred Stock
0.00
0.00
0.00
—
Share Issued
90.91
+1495.35%
5.70
+2.10%
5.58
+37.62%
4.06
Ordinary Shares Number
90.91
+1495.35%
5.70
+2.10%
5.58
+37.62%
4.06
Additional Paid In Capital
780.86
+45.24%
537.62
+1.64%
528.96
+17.34%
450.79
Retained Earnings
-594.55
-15.37%
-515.36
-7.84%
-477.90
-26.85%
-376.74
Gains Losses Not Affecting Retained Earnings
-0.11
+10.66%
-0.12
-2.52%
-0.12
+0.00%
-0.12
Other Equity Adjustments
-0.11
+10.66%
-0.12
-2.52%
-0.12
+0.00%
-0.12
Total Equity Gross Minority Interest
186.29
+741.08%
22.15
-56.65%
51.10
-30.99%
74.05
Total Capitalization
262.58
+169.11%
97.57
-7.66%
105.67
-0.65%
106.36
Working Capital
235.82
+197.38%
79.30
-20.07%
99.21
-6.71%
106.35
Invested Capital
262.58
+169.11%
97.57
-7.66%
105.67
-1.86%
107.67
Total Debt
77.28
-1.03%
78.09
+33.98%
58.28
+51.69%
38.42
Net Debt
—
19.73
—
—
Capital Lease Obligations
0.99
-62.65%
2.66
-28.29%
3.71
-22.70%
4.80
Net Tangible Assets
159.69
+3169.76%
-5.20
-115.41%
33.75
-40.48%
56.70
Tangible Book Value
159.69
+3169.76%
-5.20
-115.41%
33.75
-40.48%
56.70
Derivative Product Liabilities
0.98
-92.90%
13.76
-12.29%
15.68
-32.20%
23.13
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-85.62
+34.59%
-130.90
-35.63%
-96.51
-25.17%
-77.10
Cash Flow From Continuing Operating Activities
-85.62
+34.59%
-130.90
-35.63%
-96.51
-25.17%
-77.10
Net Income From Continuing Operations
-79.20
-111.48%
-37.45
+62.98%
-101.17
-7.78%
-93.87
Depreciation Amortization Depletion
1.28
+60.43%
0.80
+89.98%
0.42
-18.32%
0.51
Depreciation And Amortization
1.28
+60.43%
0.80
+89.98%
0.42
-18.32%
0.51
Other Non Cash Items
3.36
+86.46%
1.80
-20.93%
2.28
-6.44%
2.44
Stock Based Compensation
4.30
-47.61%
8.20
-5.56%
8.69
+67.09%
5.20
Asset Impairment Charge
—
—
0.00
0.00
Operating Gains Losses
-12.78
+88.05%
-106.93
-1411.56%
-7.07
-345.54%
2.88
Gain Loss On Investment Securities
-12.78
-562.76%
-1.93
+72.75%
-7.07
-345.54%
2.88
Change In Working Capital
-2.58
-196.30%
2.67
+677.62%
0.34
-94.00%
5.74
Change In Receivables
0.50
+146.45%
-1.07
0.00
0.00
Changes In Account Receivables
0.50
+146.45%
-1.07
0.00
0.00
Change In Inventory
-1.66
+41.00%
-2.82
0.00
0.00
Change In Prepaid Assets
4.25
+521.96%
0.68
+149.85%
-1.37
-124.59%
-0.61
Change In Payables And Accrued Expense
-5.00
-172.70%
6.88
+142.19%
2.84
-60.68%
7.23
Change In Accrued Expense
-2.02
-128.25%
7.17
+345.83%
1.61
-57.72%
3.80
Change In Payable
-2.98
-941.61%
-0.29
-123.18%
1.23
-63.97%
3.42
Change In Account Payable
-2.98
-941.61%
-0.29
-123.18%
1.23
-63.97%
3.42
Change In Other Working Capital
1.08
—
—
—
Change In Other Current Assets
—
—
0.00
0.00
Change In Other Current Liabilities
-1.74
-73.31%
-1.00
+10.99%
-1.13
-27.89%
-0.88
Investing Cash Flow
8.15
-87.83%
66.99
+550.11%
-14.88
-14349.51%
-0.10
Cash Flow From Continuing Investing Activities
8.15
-87.83%
66.99
+550.11%
-14.88
-14349.51%
-0.10
Net PPE Purchase And Sale
0.00
+100.00%
-0.33
-443.33%
-0.06
+41.75%
-0.10
Purchase Of PPE
0.00
+100.00%
-0.33
-443.33%
-0.06
+41.75%
-0.10
Capital Expenditure
-3.00
+59.05%
-7.33
-12110.00%
-0.06
+41.75%
-0.10
Net Investment Purchase And Sale
11.15
+136.35%
-30.68
-107.00%
-14.82
0.00
Purchase Of Investment
-63.39
-10.95%
-57.13
-239.62%
-16.82
0.00
Sale Of Investment
74.54
+181.82%
26.45
+1222.50%
2.00
0.00
Net Intangibles Purchase And Sale
-3.00
+57.14%
-7.00
0.00
0.00
Purchase Of Intangibles
-3.00
+57.14%
-7.00
0.00
0.00
Net Other Investing Changes
—
105.00
—
—
Financing Cash Flow
238.63
+1075.85%
20.29
-77.07%
88.52
-24.49%
117.23
Cash Flow From Continuing Financing Activities
238.63
+1075.85%
20.29
-77.07%
88.52
-24.49%
117.23
Net Issuance Payments Of Debt
0.00
-100.00%
20.00
-2.13%
20.44
+2670.57%
-0.80
Issuance Of Debt
0.00
-100.00%
20.00
-11.11%
22.50
0.00
Repayment Of Debt
0.00
0.00
+100.00%
-2.06
-159.62%
-0.80
Long Term Debt Issuance
0.00
-100.00%
20.00
-11.11%
22.50
0.00
Long Term Debt Payments
0.00
0.00
+100.00%
-2.06
-159.62%
-0.80
Net Long Term Debt Issuance
0.00
-100.00%
20.00
-2.13%
20.44
+2670.57%
-0.80
Net Common Stock Issuance
238.53
0.00
-100.00%
60.00
-51.07%
122.63
Common Stock Payments
—
—
0.00
0.00
Repurchase Of Capital Stock
—
—
0.00
0.00
Proceeds From Stock Option Exercised
0.10
-66.67%
0.29
-96.63%
8.71
+4088.46%
0.21
Net Other Financing Charges
—
—
-0.63
+86.89%
-4.81
Changes In Cash
161.16
+469.50%
-43.62
-90.64%
-22.88
-157.16%
40.02
Effect Of Exchange Rate Changes
0.21
+236.54%
-0.16
-257.58%
0.10
+194.29%
-0.10
Beginning Cash Position
56.48
-43.66%
100.25
-18.52%
123.03
+48.03%
83.11
End Cash Position
217.85
+285.75%
56.48
-43.66%
100.25
-18.52%
123.03
Free Cash Flow
-88.62
+35.89%
-138.23
-43.13%
-96.57
-25.09%
-77.20
Interest Paid Supplemental Data
8.05
+3.70%
7.77
+68.68%
4.60
+53.16%
3.01
Common Stock Issuance
238.53
0.00
-100.00%
60.00
-51.07%
122.63
Issuance Of Capital Stock
238.53
0.00
-100.00%
60.00
-51.07%
122.63
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category